Incyte: COVID PH3 Ruxolitinib in patients with COVID-19 ARDS requiring Ventilation - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about how the study drug (Ruxolitinib) effects people that are on a ventilator and have been infected with COVID-19.
COVID-19 infection needing a ventilator
Who Can Participate in the Study?
Anyone over age 12 diagnosed with COVID-19 who
- Are on a ventilator
- Do not have kidney disease
- Do not have any other infections
What is Involved?
If you choose to join this study you will:
-Be randomized (like drawing numbers out of a hat) to 1 of 3 groups:
--Group 1 will get 5mg of the study drug (Ruxolitinib)
--Group 2 will get 15mg of the study drug (Ruxolitinib)
--Group 3 will get a placebo (harmless sugar pill)
-Agree to join the study for 1 month
-Complete a follow-up phone call 28 days after taking your last dose of medicine
*If you leave the hospital, you will receive a phone call on days 15 and 29